Peripheral neuropathic pain induced by the chemotherapeutic cisplatin can persist for months to years after treatment. Histone deacetylase 6 (HDAC6) inhibitors have therapeutic potential for cisplatin-induced neuropathic pain since they persistently reverse mechanical hypersensitivity and spontaneous pain in rodent models. Here, we investigated the mechanisms underlying reversal of mechanical hypersensitivity in male and female mice by a 2 week treatment with an HDAC6 inhibitor, administered 3 d after the last dose of cisplatin. Mechanical hypersensitivity in animals of both sexes treated with the HDAC6 inhibitor was temporarily reinstated by a single injection of the neutral opioid receptor antagonist naltrexone methiodide or the peripherally restricted opioid receptor antagonist naloxone methiodide. These results suggest that tonic peripheral opioid ligand-receptor signaling mediates reversal of cisplatin-induced mechanical hypersensitivity after treatment with an HDAC6 inhibitor. Pointing to a specific role for δ opioid receptors (DORs), Oprd1 expression was decreased in DRG neurons following cisplatin administration, but normalized after treatment with an HDAC6 inhibitor. Mechanical hypersensitivity was temporarily reinstated in both sexes by a single injection of the DOR antagonist naltrindole. Consistently, HDAC6 inhibition failed to reverse cisplatin-induced hypersensitivity when DORs were genetically deleted from advillin+ neurons. Mechanical hypersensitivity was also temporarily reinstated in both sexes by a single injection of a neutralizing antibody against the DOR ligand met-enkephalin. In conclusion, we reveal that treatment with an HDAC6 inhibitor induces tonic enkephalin-DOR signaling in peripheral sensory neurons to suppress mechanical hypersensitivity.

Key words: allodynia; CIPN; latent sensitization; opioid receptors

Significance Statement

Over one-fourth of cancer survivors suffer from intractable painful chemotherapy-induced peripheral neuropathy (CIPN), which can last for months to years after treatment ends. HDAC6 inhibition is a novel strategy to reverse CIPN without negatively interfering with tumor growth, but the mechanisms responsible for persistent reversal are not well understood. We built on evidence that the endogenous opioid system contributes to the spontaneous, apparent resolution of pain caused by nerve damage or inflammation, referred to as latent sensitization. We show that blocking the δ opioid receptor or its ligand enkephalin unmasks CIPN in mice treated with an HDAC6 inhibitor (latent sensitization). Our work provides insight into the mechanisms by which treatment with an HDAC6 inhibitor apparently reverses CIPN.

Introduction

Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect experienced by 25%-30% of patients receiving treatment for cancer and can persist for months to years (Flatters et al., 2017). Among patients treated with platinum-based agents, the incidence of neuropathy is even higher (70%-100%) (McWhinney et al., 2009; Banach et al., 2017; Zajaczkowska et al., 2019). With limited treatment options available, new approaches to alleviate the symptoms of CIPN are urgently needed (Cavaletti et al., 2019; Colvin, 2019). Histone deacetylase 6 (HDAC6) inhibition has potential as a novel strategy to prevent or reverse peripheral neuropathies induced by cisplatin, paclitaxel, or vincristine (Krukowski et al., 2017; Van Helleputte et al., 2018; Ma et al., 2019; J. Zhang et al., 2022);
reversal is especially attractive as it does not interfere with the primary cancer treatment. HDAC6 is predominantly a cytosolic deacetylase that deacylates nonhistone proteins, including tubulin and heat shock proteins, ultimately regulating processes such as intracellular protein trafficking and degradation (Hubbert et al., 2002; Bali et al., 2005). Consequently, HDAC6 inhibitors restore axonal mitochondrial content and function after treatment with cisplatin or vincristine (Krukowski et al., 2017; Van Helleputte et al., 2018; Ma et al., 2019; J. Zhang et al., 2022). In contrast to other agents that suppress CIPN in preclinical models (for review, see Flatters et al., 2017), a 2 week course of dosing with an HDAC6 inhibitor persistently reverses peripheral neuropathy induced by cisplatin and paclitaxel (Krukowski et al., 2017; Ma et al., 2019; J. Zhang et al., 2022). We have shown that conditional KO of Hdac6 in adullin+ sensory neurons only partially attenuates mechanical hypersensitivity (Ma et al., 2019), indicating that the pain-resolving effects of HDAC6 inhibitors rely on as yet to be elucidated intercellular communication. In addition, it is not known whether reversal of cisplatin-induced mechanical hypersensitivity by HDAC6 inhibitors represents a true return to baseline or whether hypersensitivity is suppressed by ongoing cell–cell signaling.

There is evidence that the endogenous opioid system contributes to the apparent resolution of pain caused by traumatic nerve injury, inflammation, or a short course of chemotherapy (Corder et al., 2013; Marvizon et al., 2015; Inyang et al., 2021). After pain has spontaneously resolved in these models, inhibition of opioid receptor signaling leads to reinstatement of mechanical hypersensitivity. For example, antagonists for μ, δ, and κ opioid receptors (MOR, DOR, KOR, respectively) reinstate nociceptive hypersensitivity after resolution of inflammatory pain induced by intraplantar complete Freund’s adjuvant (CFA) (Corder et al., 2013; Walwyn et al., 2016). The spontaneous resolution of CIPN induced by a short (3 d) course of cisplatin is maintained by coupling between MORs and DORs (heteromers) (Inyang et al., 2021). These findings indicate that, after tissue healing, the resolution of pain depends on transition of the nervous system into a novel state referred to as latent sensitization, in which the suppression of hypersensitivity is maintained by tonic endogenous opioid signaling (Corder et al., 2013; Marvizon et al., 2015; Pereira et al., 2015).

Here, we evaluated whether the persistent reversal of long-lasting mechanical hypersensitivity (≈70 d) induced by two 5 d cycles of cisplatin by an HDAC6 inhibitor represents a true return to baseline or a transition to latent sensitization. We show that the reversal of cisplatin-induced mechanical hypersensitivity by an HDAC6 inhibitor is sustained by tonic activation of DOR in peripheral sensory neurons by its endogenous ligand enkephalin.

Materials and Methods

Animals. Male and female C57BL/6J mice (8-10 weeks of age) were purchased from The Jackson Laboratory (#000664). Male and female Hdac6+/− mice on a C57/Bl6 background were kindly provided by Patrick Matthias (Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland) (Y. Zhang et al., 2008). Avil+/−/Oprd1+/+ mkg were obtained by crossing Avil+/−/mkg (#032536, The Jackson Laboratory) (Zhou et al., 2010) with Oprd1+/+ mice (kindly provided by Gregory Scherrer, UNC School of Medicine) (D. Wang et al., 2018). All mutant mice were genotyped before inclusion in experiments (TransnetYY), and WT littermates were used as controls. Mice were maintained at the University of Texas M. D. Anderson Cancer Center animal facility and group-housed in individually ventilated cages on a regular 12 h light/dark cycle with free access to food and water. All experimental procedures were consistent with the National Institute of Health’s Guide for the care and use of laboratory animals, and were approved by the M. D. Anderson Animal Care and Use Committee. Mice were randomly assigned to experimental groups, and all analyses were performed by investigators who were blinded to group assignments.

Drug administration. Cisplatin (#NDC 16729-288-11, TEVA Pharmaceuticals) was diluted in sterile PBS (#21-040-CV, Corning) to a concentration of 0.23 mg/ml and administered intraperitoneally at a dose of 2.3 mg/kg per day for 5 d followed by 5 d of rest and another 5 d of injections (Krukowski et al., 2017). The HDAC6 inhibitor ACY-1083 (Regency Pharmaceuticals) was prepared in vehicle consisting of 20% 2-hydroxypropyl-β-cyclodextrin (#297565000, ACROS Organics) and 0.5% hydroxypropyl methylcellulose (#HY124, Spectrum Chemical) in sterile water (Krukowski et al., 2017). Three days after completion of cisplatin treatment, mice received daily intraperitoneal injections of ACY-1083 at a dose of 10 mg/kg for 2 weeks (Krukowski et al., 2017). Naltrexone hydrochloride (#N3136, Millipore Sigma) was freshly dissolved in sterile PBS and was injected subcutaneously at the nape of the neck at a dose of 3 mg/kg (Marvizon et al., 2015). 6J -Naltrexol hydrate (#N9412, Millipore Sigma) was freshly dissolved in 1% DMSO diluted with sterile H2O and was injected subcutaneously at the nape of 10 mg/kg (Walwyn et al., 2016). Naltirindole hydrochloride (#N115, Millipore Sigma) was freshly dissolved in sterile saline and was injected subcutaneously at the nape with a dose of 3 mg/kg (Walwyn et al., 2016). D-Phe-Cys-Tyr-Krt-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP, #HY-P1329A, MedChemExpress) was freshly dissolved in sterile saline and was injected subcutaneously at the nape of 10 mg/kg (Gerhold et al., 2015). D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP; #HY-P1335A, MedChemExpress) was freshly dissolved in sterile H2O and was injected subcutaneously at the nape with a dose of 1 mg/kg (Bartlett et al., 2020). Anti-enkephalin antibody (#T-4293, BMA Biomedicals) or control IgG (#I5006, Millipore Sigma) was reconstituted in sterile water at a concentration of 2 μg/μl and intrathecally injected (10 μg per mouse) (Celkic et al., 2020).

Intrathecal injections. Mice were lightly anesthetized with 1.5% isoflurane, and the fur was shaved to expose the skin of the lower back. A 27 G needle was inserted in the interspace between L4 and L5, and a sudden tail flick was used as indication of successful entry of the needle into the intradural space, as we have previously described (Krukowski et al., 2017).

von Frey test. Mechanical sensitivity was measured using the up and down method with von Frey hairs (0.07, 0.16, 0.4, 0.6, 1.0, and 1.4 g) (Stoeling) as described previously (Chaplan et al., 1994; Krukowski et al., 2017).

RT-PCR. Mice were killed by CO2 (time point for the analysis of changes of Oprd1: 24 h after completion of ACY-1083 treatment; time point for validation of Avil+−/−:Oprd1+−, 8 weeks old after birth) and transcardially perfused with ice-cold PBS. Lumbar DRGs and lumbar spinal cord (L4-L6) were collected and saved in the liquid nitrogen. Total RNA was extracted from these tissues using TRIzol (#15596018, Invitrogen) and converted to cDNA with the high-capacity cDNA reverse transcription kit (#4368813, Applied Biosystems). Gene expression level was measured with the following primers: Mouse-Penk-forward: CTA CAG TGC AGG CGG AAT GCA; Mouse-Penk-reverse: AGG AGA TTC TGT CAG GTC TTC C; Mouse-Pomp-forward: TGG TGC CAG GAC AGC CAG; Mouse-Pomp-reverse: GGG GTT CCT TAC GAG GGT CCT; Mouse-Pyd-nforward: TCA ACC CCC TGA TTT GCT CC; Mouse-Pyd-nreverse: TTC AAC AGC TGG GCT AGT GC; Mouse-Oprd1-forward: ACC AGA AAG GTG GCT GAG TG; Mouse-Oprd1-reverse: TGT ACT GGC ACT GGG GTT AC; Mouse-Oprm1-forward: TCT GCC ATT GTG CCT CCC; GATA; Mouse-Oprm1-reverse: GAT GAG CCG CAT GAT GAA GCC;
Mouse-Oprk1-forward: ATG AGT GTG GAC CGC ATT GCT G; Mouse-Oprk1-reverse: CAG GAA ACT GCA AGG AGC ATT C, normalized to Tubα1a, Mouse-Tubα1a-forward: CCA CTA CAC CAT TGG CAA GGA GA; Mouse-Tubα1a-reverse: GGA GGT GAA GCC AGA GCT AGT. Quantitative amplification was performed using the SybrGreen (Bio-Rad) with a running program (95°C 3 min and 40 cycles of 95°C for 5 s and 60°C for 30 s).

RNA 5SH (RNAseq). Mice were killed by CO2 (time point for the analysis of Oprd1 24 h after completion of ACY-1083 treatment; time point for validation of Avil after Oprd1 8 weeks after birth) and transcardially perfused with ice-cold PBS. Lumbar DRGs were embedded and freshly frozen in Tissue-Tek OCT Compound (#4583, Sakura). Tissues were cut at 12 μm using a Leica CM3050S cryostat. The RNAscope Fluorescent Multiplex Assay (#320851, Advanced Cell Diagnostics) was used according to the manufacturer's instructions. Briefly, slides were fixed in cold fresh 10% Neutral Buffered Formalin for 15 min and subsequently dehydrated in 50%, 70%, and 100% ethanol. Slides were pretreated with RNAscope Protease IV and hybridized with RNAscope probes following the protocol. Probes used are as follows: Mm-Oprd1 (DOR, #427371, Advanced Cell Diagnostics), Mm-Nefh-C2 (NF200, #443671-C2, Advanced Cell Diagnostics), Mm-P2rx3-C3 (P2XR3, #521611-C3, Advanced Cell Diagnostics), and Mm-Calca2-C2 (GGRP, #578771-C2, Advanced Cell Diagnostics). Sections were imaged using a Nikon A1R Confocal Microscope. The percentages of neurons expressing Oprd1 (>5 puncta per cell) were calculated by dividing the number of Nefh+, P2rx3+, or Calca2+ neurons positive for Oprd1 by the total number of respective Nefh+, P2rx3+, or Calca2+ neurons. Individual neurons were defined as ROIs. The mean intensity of each ROI was used to estimate mRNA abundance, and was analyzed using NIS Elements (Nikon).

**Results**

**Endogenous opioid receptor signaling mediates persistent reversal of cisplatin-induced mechanical hypersensitivity after HDAC6 inhibitor treatment**

HDAC6 inhibitors are attractive therapeutics for CIPN because 2 weeks of administration of ACY-1083, a specific HDAC6 inhibitor, results in persistent reversal of cisplatin-induced mechanical hypersensitivity and spontaneous pain (Krukowski et al., 2017; Ma et al., 2019; J. Zhang et al., 2022). In search for a mechanism of action, we first tested whether the reversal of cisplatin-induced hypersensitivity in response to the HDAC6 inhibitor is mediated via sustained activation of opioid signaling. Cisplatin-induced mechanical hypersensitivity was established as described previously (Krukowski et al., 2017): male and female mice received two rounds of cisplatin (2.3 mg/kg/d, i.p., 5 d on, 5 d rest, and 5 d on) (Fig. 1A). In line with our previous studies (Krukowski et al., 2017; Ma et al., 2019; J. Zhang et al., 2022), administration of the HDAC6 inhibitor ACY-1083 (10 mg/kg/d, i.p., 14 d) starting 3 d after the last dose of cisplatin resulted in long-lasting reversal of mechanical hypersensitivity (Fig. 1B). One day after HDAC6 inhibitor treatment finished, a single injection of naltrexone (3 mg/kg, i.p., 15 min) and subsequently dehydrated in 50%, 70%, and 100% ethanol. Slides were pretreated with RNAscope Protease IV and hybridized with RNAscope probes following the protocol. Probes used are as follows: Mm-Oprd1 (DOR, #427371, Advanced Cell Diagnostics), Mm-Nefh-C2 (NF200, #443671-C2, Advanced Cell Diagnostics), Mm-P2rx3-C3 (P2XR3, #521611-C3, Advanced Cell Diagnostics), and Mm-Calca2-C2 (GGRP, #578771-C2, Advanced Cell Diagnostics). Sections were imaged using a Nikon A1R Confocal Microscope. The percentages of neurons expressing Oprd1 (>5 puncta per cell) were calculated by dividing the number of Nefh+, P2rx3+, or Calca2+ neurons positive for Oprd1 by the total number of respective Nefh+, P2rx3+, or Calca2+ neurons. Individual neurons were defined as ROIs. The mean intensity of each ROI was used to estimate mRNA abundance, and was analyzed using NIS Elements (Nikon).

**Expression of DORs in DRG is decreased by cisplatin and normalized by HDAC6 inhibitor treatment**

The antagonists evaluated in previous experiments inhibit all three opioid receptors (D. Wang et al., 2007). To determine whether expression of specific opioid receptors was altered by cisplatin and/or the HDAC6 inhibitor, we used RT-PCR to quantify the expression levels of Oprd1, Oprm1, and Oprk1. We detected changes only in Oprd1 expression: cisplatin treatment alone decreased Oprd1 mRNA levels in the DRG, whereas treatment with the HDAC6 inhibitor normalized expression of Oprd1 in both sexes (Fig. 3A). As mechanical hypersensitivity was reinstated by the neutral opioid receptor antagonist (Fig. 1), suggesting a role for endogenous ligands, we also quantified expression of opioid peptide precursors Penk, Pomc, and Pdyn in DRG. However, gene expression was unchanged by cisplatin or the HDAC6 inhibitor (Fig. 3A). Aligning with our finding that a peripheral blockade of opioid receptors was sufficient to reinstate mechanical hypersensitivity, gene expression levels of opioid receptors and opioid peptide precursors did not change in spinal cord as a consequence of cisplatin and/or HDAC6 inhibitor treatment (Fig. 3B).

Next, we used RNAscope analysis to determine whether the cisplatin-induced decrease in Oprd1 mRNA expression occurred in a specific subset of DRG neurons from male and

Naltrexone is an inverse agonist; therefore, the reinstatement of mechanical hypersensitivity could be mediated by either a decrease in the constitutive activity of opioid receptors or by inhibition of the activity of an endogenous agonist. We next used 6β-naltrexol, a neutral opioid receptor antagonist, to test whether endogenous opioids binding to their receptors contribute to the persistent reversal of cisplatin-induced mechanical hypersensitivity in response to administration of the HDAC6 inhibitor. Injection of 6β-naltrexol (10 mg/kg, s.c.) temporarily reinstated mechanical hypersensitivity in male and female mice treated with cisplatin and the HDAC6 inhibitor (Fig. 1B,C). Neither naltrexone nor 6β-naltrexol altered mechanical thresholds of mice previously treated with cisplatin alone, HDAC6 inhibitor alone, or vehicle controls. These data suggest that binding of endogenous ligand to opioid receptors mediates the persistent reversal of cisplatin-induced mechanical hypersensitivity after HDAC6 inhibitor treatment in both sexes.
female mice (Fig. 4A,B). We found that >50% Nefh+ neurons (a marker for large-diameter, myelinated neurons) express Oprd1 (Fig. 4C), consistent with a previous report (Bardoni et al., 2014). We did not detect cisplatin-induced changes in the percentage of Nefh+ neurons expressing Oprd1. However, the level of expression of Oprd1 mRNA in Nefh+ neurons was significantly decreased by cisplatin, and normalized by treatment with the HDAC6 inhibitor (Fig. 4C, D). In addition, we observed expression of Oprd1 by P2rx3+ neurons (a marker for peptidergic nociceptors) and Calca+ neurons (a marker for peptidergic neurons) (Fig. 4A,B), consistent with previous reports (Bardoni et al., 2014). Cisplatin again did not alter the proportion of P2rx3+ (≈60%) or Calca+ neurons (near 30%) expressing Oprd1, but Oprd1 expression levels were reduced in both subsets (Fig. 4E–H). The HDAC6 inhibitor normalized Oprd1 expression levels (Fig. 4F,H). Together, these data demonstrate that Oprd1 expression was decreased by cisplatin in mechanoreceptors, and peptidergic and nonpeptidergic nociceptors, and normalized by HDAC6 inhibitor treatment.
Figure 2. Naloxone methiodide reinstated cisplatin-induced mechanical hypersensitivity after reversal by HDAC6 inhibitor treatment. (A) Timeline of the experimental design and von Frey test. Three days after completion of cisplatin treatment (2.3 mg/kg/day, i.p., 5 days on, 5 days rest, 5 days on), mice were treated with ACY-1083 for 14 consecutive days (10 mg/kg/day, i.p.). The peripherally-restricted opioid receptor antagonist naloxone methiodide (5 mg/kg, s.c.) was injected after completion of ACY-1083. Mechanical hypersensitivity (von Frey testing) was monitored at given time points. (B-C), Paw withdrawal threshold from von Frey test in (B) male (interaction: $F_{21,84} = 8.658, p < 0.0001$) and (C) female mice (interaction: $F_{21,84} = 8.287, p < 0.0001$). *$p < 0.05$; **$p < 0.01$; cisplatin + ACY-1083 versus PBS (two-way ANOVA with Dunnett post hoc test), $n = 4$ mice per groups for both males and females.
DOR and enkephalin mediate the persistent reversal of cisplatin-induced mechanical hypersensitivity after HDAC6 inhibitor treatment

As DOR gene expression in sensory neurons was regulated by cisplatin and ACY-1083, we used the selective DOR antagonist naltrindole to test whether DOR mediates the persistent reversal of cisplatin-induced mechanical hypersensitivity after HDAC6 inhibitor treatment. Mice were treated with cisplatin followed by the HDAC6 inhibitor to normalize mechanical sensitivity (Fig. 5A). One day after the HDAC6 inhibitor treatment was finished,
Figure 4. Expression of DORs was decreased by cisplatin and reversed by ACY-1083 in mouse DRG neurons. A, RNAscope was used to detect Oprd1 mRNA abundance in neurons positive for Nefh (encoding NF200 for mechanoreceptors) and P2rx3 (encoding P2X3R for nonpeptidergic nociceptors). Scale bar, 100 μm. B, RNAscope was used to detect Oprd1 mRNA abundance in neurons positive for Calca (encoding CGRP for peptidergic nociceptors). Scale bar, 10 μm. C, Percentages of Nefh DRG neurons also positive for Oprd1. N = 8 sections from 4 male mice per group. D, Oprd1 mRNA abundance in Nefh DRG neurons. **p < 0.01; ***p < 0.001; Kruskal–Wallis test with Dunn’s post hoc test. n = 99 neurons for PBS, 67 neurons for cisplatin, and 100 neurons for cisplatin + ACY-1083 from 4 male mice per group. E, Percentages of P2rx3 DRG neurons also positive for Oprd1. N = 8 sections from 4 male mice per group. F, Oprd1 mRNA abundance in P2rx3 DRG neurons. ***p < 0.001 (Kruskal–Wallis test with Dunn’s post hoc test). n = 82 neurons for PBS, 89 neurons for cisplatin, and 96 neurons for cisplatin + ACY-1083 from 4 male mice per group. G, Percentages of Cgrp neurons also positive for Oprd1. N = 11-14 sections from 4 male mice per group. H, Oprd1 mRNA abundance in Cgrp DRG neurons. *p < 0.05 (Kruskal–Wallis test with Dunn’s post hoc test). n = 74 neurons for PBS, 102 neurons for cisplatin, and 78 neurons for cisplatin + ACY-1083 from 4 male mice per group.
a single injection of naltrindole (3 mg/kg, s.c.) temporarily reinstated mechanical hypersensitivity in male and female mice treated with cisplatin followed by the HDAC6 inhibitor (Fig. 5B,C).

In contrast, mechanical hypersensitivity was not reinstated by single injections of the MOR inverse agonist CTOP or neutral antagonist CTAP, or the KOR inverse agonist norBNI (Fig. 5D,E). These results collectively suggest that sustained activation of DOR persistently reverses mechanical hypersensitivity in mice of both sexes treated with cisplatin followed by the HDAC6 inhibitor.

To confirm that DOR in sensory neurons contributes to the reversal of cisplatin-induced mechanical hypersensitivity in response to treatment with the HDAC6 inhibitor, we used Avil
colored
colored

cre:Oprd1fl/fl mice. We verified that Oprd1 was genetically deleted from sensory neurons, but not the spinal cord (Fig. 6A–C). The HDAC6 inhibitor did not reverse cisplatin-induced mechanical hypersensitivity in male or female Avil
colored
colored

cre:Oprd1fl/fl mice, while Avil
colored
colored

cre:Oprd1fl/fl littermate controls responded similarly to WT mice (Fig. 6D). These data indicate that DOR expression in sensory neurons mediates the persistent reversal of cisplatin-induced mechanical hypersensitivity by HDAC6 inhibition.

Our finding that the neutral opioid receptor antagonist reinstated mechanical hypersensitivity (Fig. 1) suggested a role for endogenous ligands. We therefore evaluated whether the endogenous DOR ligand enkephalin contributes to persistent reversal of cisplatin-induced mechanical hypersensitivity after treatment with the HDAC6 inhibitor (Fig. 7A). Intrathecal injection of neutralizing antibody (2 μg) to inhibit enkephalin in DRG reinstated mechanical hypersensitivity in male and female mice treated with cisplatin and the HDAC6 inhibitor, compared with IgG control (2 μg, i.t.; Fig. 7B,C). Together, these results suggest that enkephalin-DOR signaling maintains persistent reversal of cisplatin-induced hypersensitivity after HDAC6 inhibition in mice of both sexes.

Enkephalin-DOR signaling does not mediate prevention of cisplatin-induced mechanical hypersensitivity by HDAC6 inhibition

We previously showed that HDAC6 inhibitors can also prevent cisplatin-induced hypersensitivity, while Hdad6−/− mice do not develop mechanical hypersensitivity (Ma et al., 2019). We asked...
whether tonic endogenous opioid signaling contributes to the prevention of mechanical hypersensitivity after coadministration of the HDAC6 inhibitor with cisplatin. Consistent with our previous findings, cisplatin induced hypersensitivity in male and female WT mice but not in the \( \text{Hdac6}^{-/-} \) mice (Fig. 8A) (Ma et al., 2019). However, neither naltrindol nor naltrexone reinstated mechanical hypersensitivity in \( \text{Hdac6}^{-/-} \) mice (Fig. 8A). Moreover, naltrexone did not reinstate mechanical hypersensitivity in male mice where cisplatin and the HDAC6 inhibitor were coadministered (Fig. 8B). Together, these data indicate that prevention of cisplatin-induced mechanical hypersensitivity by HDAC6 inhibitors is independent of enkephalin-DOR signaling.

### Discussion

We have discovered that DOR expressed by peripheral sensory neurons and its endogenous ligand enkephalin are responsible for apparent resolution of cisplatin-induced mechanical hypersensitivity after treatment with an HDAC6 inhibitor, in both sexes. In this context, the HDAC6 inhibitor therefore generates a state of latent sensitization in which cisplatin-induced mechanical hypersensitivity is tonically suppressed, rather than truly resolved (returned to the pre-injury state), summarized in Figure 9.

Our data show that opioid signaling in the peripheral nervous system tonically suppresses cisplatin-induced mechanical hypersensitivity in response to HDAC6 inhibition. This is different from latent sensitization after spontaneous recovery from inflammatory pain induced by CFA where systemic injection of a peripherally restricted opioid receptor antagonist, naltrexone methobromide, failed to reinstate nociceptive hypersensitivity (Corder et al., 2013). However, in a model of ocular neuropathic pain, spontaneously resolved nociceptive hypersensitivity was reinstated by topical naloxone methiodide, indicating the contribution of peripheral opioid signaling in suppression of ocular pain (Cho et al., 2019). These data suggest that there are injury-specific differences in the opioid responses that suppress pain in states of latent sensitization. These differences may reflect the local needs or microenvironments of the injured tissues, including the local capacity to produce enkephalin and/or express DOR.
We further show that apparent resolution of mechanical allodynia (latent sensitization) following treatment with an HDAC6 inhibitor is dependent on the DOR ligand enkephalin. This again differs from the CFA model, where remission of hypersensitivity was maintained by constitutive MOR activity (Corder et al., 2013) (which had no role in latent sensitization following treatment with an HDAC6 inhibitor). Although the gene encoding proenkephalin is expressed in a subpopulation of human and mouse DRG neurons (Sapio et al., 2020; Tavares-Ferreira et al., 2022), Penk mRNA expression was unchanged in DRG of mice treated with cisplatin followed by the HDAC6 inhibitor. These data suggest a source other than sensory neurons, and the cells...
that secrete enkephalin following treatment with HDAC6 inhibitors will be investigated in future studies. One possible source would be immune cells, which are capable of secreting opioid peptides ([Heijnen et al., 1991](#)). For example, repeated interleukin-4 treatment increased the expression of endogenous opioid peptides in macrophages, thereby alleviating nociceptive hypersensitivity because of peripheral nerve injury ([Celik et al., 2020](#); [Labuz et al., 2021](#)). In addition, opioid peptides produced by CD4<sup>+</sup> T cells in the inflamed gut contribute to pain control in models of inflammatory bowel disorder ([Boue et al., 2014](#)). It was also reported that opioid peptides produced by T cells suppress pain during late pregnancy ([Rosen et al., 2017](#)). The upstream regulators of endogenous opioids in immune cells still need to be defined in the context of treatment with HDAC6 inhibitors. We have previously shown that interleukin-10 also mediates the apparent resolution of cisplatin-induced mechanical hypersensitivity after treatment with an HDAC6 inhibitor ([J. Zhang et al., 2022](#)). Interleukin-10 may be upstream of enkephalin production, as this cytokine can regulate secretion of endogenous opioids during neuropathic pain ([Wu et al., 2017, 2018](#)). Collectively, these studies reveal that crosstalk between the immune and opioid systems contributes to reduced neuronal hyperexcitability. Such signaling may be exploited to manage chronic pain ([Kavelaars and Heijnen, 2021](#)), potentially using HDAC6 inhibitors.

It is yet to be determined how treatment with the HDAC6 inhibitor restores *Oprd1* expression. Although HDAC6 primarily acts in the cytosol ([Hubbert et al., 2002; Bali et al., 2005](#)), the normalization of *Oprd1* expression following treatment with the HDAC6 inhibitor points to transcriptional control. *In vitro* studies show that residual nuclear HDAC6 can acetylate histones directly, or indirectly through repression of histone acetyltransferases ([Girdwood et al., 2003; Liu et al., 2012; García-Domínguez et al., 2020](#)). HDAC6 may also regulate *Oprd1*
indirectly through cytosolic interactions with unknown negative regulators. Future studies will therefore evaluate whether HDAC6 inhibitors increase histone acetylation in the Oprd1 promoter region. It is also possible that the long duration of treatment with the HDAC6 inhibitor engages other repair mechanisms that indirectly restore Oprd1 expression (e.g., enhanced interleukin-10 signaling, recovered mitochondrial function).

An intriguing observation is that opioid receptor antagonists did not restate mechanical hypersensitivity when the HDAC6 inhibitor was used to prevent neuropathic pain or in Hdc6<−/− mice. First, this finding suggests that a previous painful experience is necessary for the establishment of latent sensitization. Pain-related behaviors induced by nerve injury, inflammation, or chemotherapy seem to be the trigger for development of latent sensitization, rather than full recovery to baseline; opioid receptor antagonists restate hypersensitivity after spontaneous recovery, but not in mice without a previous pain experience (Corder et al., 2013; Marvizon et al., 2015). The duration and/or intensity of the prior painful experience that is necessary to induce a state of latent sensitization after apparent recovery is still an open question. Nonetheless, these data demonstrate that resolution of pain is driven in part by a transition to a novel state that is associated with active opioid signaling and sustained changes in gene expression in the nervous system (latent sensitization). Second, our current results show that tonic endogenous opioid signaling is not required to suppress mechanical hypersensitivity if CIPN was prevented by previous coadministration of the HDAC6 inhibitor with cisplatin. Chronic pain conditions can recur after a period of remission (Stanton et al., 2010), and it has been suggested that apparent remission of pain may reflect a state of latent sensitization, rather than full recovery (Inyang et al., 2021). If latent sensitization increases the risk of CIPN relapse, it may be advantageous to prevent rather than reverse cisplatin-induced mechanical hypersensitivity.

DORs are widely expressed in DRG neurons, as shown in this study and others (Bardoni et al., 2014; Francois and Scherrer, 2018), where they control hyperexcitability mediating nociception. For example, presynaptic DORs suppress glutamate release from mechanoreceptors in the spinal dorsal horn (Bardoni et al., 2014). In addition, inflammatory and neuropathic pain was exacerbated in mice lacking DOR in Na<sub>v</sub>1.8<sup>−/−</sup> nociceptors, while acute pain responses remained largely intact (Gaveriaux-Ruff et al., 2011). In this study, we found that cisplatin significantly decreased the expression of Oprd1 in Nefl<sup>−/−</sup> neurons. This result suggests that mechanoreceptors may be disinhibited following cisplatin treatment, aligning with the increase in mechanical hypersensitivity. The expression of Oprd1 in peptidergic (Calc2<sup>−/−</sup>) and nonpeptidergic (P2rx3<sup>−/−</sup>) neurons was also decreased by cisplatin treatment. These results suggest that cisplatin also disinhibits nociceptors. Future studies could evaluate which Oprd1<sup>−/−</sup> neuronal subtypes mediate hypersensitivity to other pain modalities in CIPN. There is also evidence that Oprd1 expression is downregulated in DRG in other preclinical models of neuropathic pain (Pokhilo et al., 2020). Reduced Oprd1 expression could therefore be a contributing factor to low DOR agonist efficacy in clinical pain states (Shiwarski et al., 2017; Spahn and Stein, 2017; Abdallah and Gendron, 2018). Strategies to increase Oprd1 expression, such as treatment with an HDAC6 inhibitor, may be needed to achieve DOR-mediated analgesia.

In conclusion, we report that 2 weeks of treatment with an HDAC6 inhibitor reverses cisplatin-induced mechanical hypersensitivity by inducing tonic enkephalin-DOR signaling in the peripheral nervous system. HDAC6 inhibition therefore creates a new setpoint to suppress ongoing hypersensitivity, rather than fully reversing neuroplastic changes induced by cisplatin. Further investigation is needed to determine how cisplatin and HDAC6 inhibitors dynamically regulate expression of DORs and enkephalin. Where previous studies have shown that inflammatory and neuropathic pain naturally remit through transition to a state of latent sensitization, we demonstrate that this state can be therapeutically induced to rapidly suppress CIPN long term. Importantly, this approach could be harnessed to manage CIPN and other chronic pain conditions without a need for ongoing treatment.

References


Genetic ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia. Pain 152:1238–1248.


